Oklahoma Senate Bill SB1568

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Public health; creating the Oklahoma Parental Decision-Making and Hepatitis B Immunization Act of 2026; specifying certain restrictions on hepatitis B vaccine. Effective date.

Summary

SB1568 creates the “Oklahoma Parental Decision-Making and Hepatitis B Immunization Act of 2026” and changes how Oklahoma handles hepatitis B vaccination for newborns and children. The bill states that, for infants born to mothers who test negative for hepatitis B, the timing and location of the first hepatitis B vaccine dose should be determined through shared clinical decision-making between parents and the child’s health care provider, consistent with current ACIP guidance. It also says hepatitis B vaccination may be administered in any lawful clinical setting, not just in a hospital or birthing facility. The bill preserves a different standard for infants born to mothers who are hepatitis B-positive or whose status is unknown. In those cases, birthing facilities would still be expected to offer and may administer hepatitis B immunoprophylaxis, including vaccine, as medically indicated. The measure also requires providers to inform parents about ACIP recommendations and obtain informed consent before giving a hepatitis B vaccine dose, except in emergencies where consent cannot reasonably be obtained. SB1568 would alter state law and administrative rules by prohibiting any state statute, regulation, or policy from being interpreted to require a hepatitis B birth dose in a hospital, birthing facility, or midwife practice as a condition of compliance with newborn immunization requirements. It directs the State Commissioner of Health to amend rules within 12 months to remove the universal 12-hour birth-dose requirement and to align rules with the bill’s shared-decision model for hepatitis B-negative mothers. It also provides that the bill does not change general school or child care immunization laws and that the act controls over conflicting newborn hepatitis B regulations unless later amended by the Legislature. The general sentiment reflected in the bill text is strongly supportive of parental choice and informed consent, with the measure framed as aligning Oklahoma law with updated ACIP recommendations. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or opposition in the available materials. However, the structure of the bill suggests likely tension between public health uniformity in birthing facilities and expanded parental discretion over newborn vaccination timing and setting. The main point of contention is the shift away from a universal hospital-based birth dose for infants of hepatitis B-negative mothers. Supporters would likely emphasize parental rights, shared decision-making, and flexibility in where vaccination occurs, while critics may be concerned about weakening a longstanding universal newborn immunization practice and complicating implementation in hospitals and midwife settings. The bill preserves mandatory prophylaxis for higher-risk infants, which may reduce some public health concerns, but it still narrows the existing universal birth-dose approach.

Impact

SB1568 would amend Oklahoma public health law by creating new statutory provisions in Title 63 governing hepatitis B vaccination for newborns and children. It would bar state and local rules from requiring the hepatitis B birth dose in a hospital or birthing facility for compliance with immunization requirements, require rulemaking by the State Commissioner of Health to remove the current universal 12-hour birth-dose mandate, and recognize hepatitis B vaccination given in outpatient or other lawful clinical settings as satisfying state requirements. It also protects parental refusal or deferral of the birth dose for hepatitis B-negative mothers and requires informed consent and provider counseling consistent with ACIP guidance.

Sentiment

The bill’s stated purpose and findings reflect a pro-parental-rights, pro-informed-consent approach, and the text repeatedly emphasizes alignment with current ACIP recommendations. No committee discussion or vote history is provided, so there is no recorded legislative debate to gauge support or opposition directly. Based on the bill language alone, the measure appears designed to appeal to advocates of medical choice and family autonomy, while likely drawing concern from public health stakeholders who favor universal newborn vaccination protocols.

Contention

The central controversy is whether Oklahoma should continue a universal hospital-based hepatitis B birth-dose requirement or move to a shared decision-making model for infants born to hepatitis B-negative mothers. Supporters of the bill are likely to argue that parents should decide the timing and setting of vaccination and that state rules should match updated ACIP guidance. Opponents are likely to focus on the public health value of a universal birth dose, the administrative burden of changing facility rules, and the possibility that more infants will miss early vaccination if the dose is deferred. The bill tries to limit that conflict by preserving immediate prophylaxis for infants of hepatitis B-positive or status-unknown mothers.